Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model.

Yoshidome,K; Shibata,M A; Maroulakou,I G; Liu,M L; Jorcyk,C L; Gold,L G; Welch,V N; Green,J E

doi:10.3892/ijo.12.2.449

Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model.

Authors:
- K Yoshidome
- M A Shibata
- I G Maroulakou
- M L Liu
- C L Jorcyk
- L G Gold
- V N Welch
- J E Green
View Affiliations

Affiliations: Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Building 41, Room C629, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Published online on: February 1, 1998 https://doi.org/10.3892/ijo.12.2.449
Pages: 449-502

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have generated a transgenic mouse model in which female mice develop ductal mammary adenocarcinomas and male mice develop prostatic adenocarcinomas by using a transgene containing the hormone-responsive rat prostatic steroid binding protein 5' flanking region C3(1) fused to the simian virus 40 (SV40) large T antigen. We have identified some genetic alterations during mammary and prostate tumor progression: (i) p53 is functionally inactivated during mammary cancer development without p53 mutations; (ii) Alterations in apoptosis during mammary tumor progression are p53 and bcl-2 independent; (iii) Ha-ras mutations occur early in the development of prostate cancer. This unique animal model offers the opportunity to study multistep tumorigenesis in these organs.